Vericel Announces Preliminary 2025 Financial Results and Business Updates
Rhea-AI Summary
Vericel (NASDAQ:VCEL) reported preliminary, unaudited 2025 results: total revenue ~$276 million comprising MACI revenue $239.5 million and Burn Care $36.5 million. Gross margin is expected at 74% and adjusted EBITDA margin at 26%. The company expects GAAP net income for the second consecutive year and ended the period with $200 million cash and investments and no debt. Q4 marks the highest quarterly counts since launch for MACI implants, implanting surgeons, surgeons taking biopsies, and MACI biopsies, with MACI revenue growth of 20%+ for a third straight year. Completed MACI sales force expansion, >900 MACI Arthro trained surgeons, initiated the MACI Ankle MASCOT study, and remain on track to begin commercial manufacturing at a new facility in 2026.
Positive
- Total revenue of $276M
- MACI revenue of $239.5M
- Gross margin of 74%
- Adjusted EBITDA margin of 26%
- Cash and investments of $200M and no debt
- MACI revenue growth of 20%+ for third consecutive year
Negative
- No full audited results or guidance provided in this preliminary release
- Commercial manufacturing only on track to begin in 2026 (timing risk)
News Market Reaction
On the day this news was published, VCEL gained 1.26%, reflecting a mild positive market reaction. This price movement added approximately $24M to the company's valuation, bringing the market cap to $1.93B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VCEL fell 5.11% while peers were mixed: some biotech names like ARDX (-3.6%) and MESO (-3.51%) declined, but others such as AUPH (+0.66%) were slightly positive. Moves do not show a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Conference appearance | Neutral | +6.1% | J.P. Morgan conference presentation timing drew a stronger-than-typical upside move. |
| Nov 14 | Conference notice | Neutral | +0.1% | Stephens conference participation update with minimal share price response. |
| Nov 06 | Quarterly earnings | Positive | +4.2% | Record Q3 revenue, strong MACI growth, and reaffirmed 2025 guidance. |
| Oct 23 | Earnings date set | Neutral | -1.2% | Scheduling of Q3 results and call with a small negative reaction. |
| Aug 28 | Conference appearance | Neutral | +0.0% | Wells Fargo conference fireside chat announcement without notable price move. |
Earnings-related releases have often coincided with sizeable moves, but direction has been mixed, with some strong results met by both gains and pullbacks.
Over the last five months, Vericel has steadily highlighted revenue growth and expanding profitability. The Q3 2025 earnings release on Nov 06, 2025 showed record revenue of $67.5M and MACI strength, drawing a 4.17% gain. Earlier 2025 earnings updates in Q1 and Q2 also reported double‑digit revenue growth, though price reactions ranged from -14.07% to 3.46%. Preliminary 2024 results on Jan 14, 2025 similarly emphasized 20%+ growth but produced a modest negative reaction, underscoring that strong fundamentals have not always translated into consistent upside.
Market Pulse Summary
This announcement outlines preliminary 2025 results with total revenue expected at $276M, including $239.5M from MACI and $36.5M from Burn Care, alongside a projected 74% gross margin and 26% adjusted EBITDA margin. Cash and investments of $200M with no debt reinforce balance sheet strength. In context of prior earnings showing similar growth, attention may focus on sustaining MACI momentum, scaling the new manufacturing facility, and tracking future profitability versus stated mid‑term targets.
Key Terms
adjusted EBITDA margin financial
AI-generated analysis. Not financial advice.
Total Revenue Expected to be
MACI Revenue Expected to be
Fourth Quarter Total Revenue and MACI Revenue Growth of
CAMBRIDGE, Mass., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced preliminary, unaudited financial results and other business updates for the fourth quarter and year ended December 31, 2025.
Preliminary, Unaudited Full-Year 2025 Financial Results
- Total net revenue expected to be approximately
$276 million , with MACI® net revenue of$239.5 million and Burn Care net revenue of$36.5 million - Gross margin expected to be
74% and adjusted EBITDA margin expected to be26% - GAAP Net Income profitability expected for the second consecutive year
$200 million in cash and investments, and no debt
Business Highlights and Updates
- Highest number of MACI implants, implanting surgeons, surgeons taking biopsies and MACI biopsies in any quarter since launch in the fourth quarter
- MACI revenue growth of
20% or more for the third consecutive year - Completed MACI sales force expansion
- More than 900 MACI Arthro® trained surgeons as of year-end 2025
- Initiated MACI Ankle™ MASCOT clinical study
- Remain on track to begin MACI commercial manufacturing in new facility in 2026
“The Company executed extremely well in 2025, delivering strong revenue and profitability growth,” said Nick Colangelo, President and CEO of Vericel. “We are entering 2026 with a great deal of momentum and expect another year of high revenue growth, increasing MACI utilization and further growth in profitability and cash generation as we continue to progress toward our mid-term financial targets.”
Vericel is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference at 2:15 p.m. ET (11:15 a.m. PT) on Wednesday, January 14, 2026. A webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the sports medicine and severe burn care markets. The Company combines innovations in biology with medical technologies, resulting in a highly differentiated portfolio of innovative cell therapies and specialty biologics that repair injuries and restore lives. Vericel markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to
Epicel®, MACI® and MACI Arthro® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2026 Vericel Corporation. All rights reserved.
Preliminary and Unaudited Nature of Reported Results
Our revenue expectations for the fourth quarter and full-year ended 2025, as well as our estimates concerning net income, gross margin, adjusted EBITDA margin and cash and investments are preliminary, unaudited and are subject to change based on the completion of ongoing internal control, review, and audit procedures. As a result, these amounts may differ materially from the amounts that will be reflected in the Company’s consolidated financial statements for the year ended December 31, 2025. Accordingly, you should not place undue reliance on this preliminary estimate.
GAAP v. Non-GAAP Measures
Vericel’s expected and reported earnings are prepared in accordance with generally accepted accounting principles in the United States, or GAAP, and represent earnings as reported to the Securities and Exchange Commission. Vericel has provided in this release certain financial information that has not been prepared in accordance with GAAP. Vericel’s management believes that the non-GAAP adjusted EBITDA margin described in this release, which includes adjustments for specific items that are generally not indicative of our core operations, provides additional information that is useful to investors in understanding Vericel’s underlying performance, business and performance trends, and helps facilitate period-to-period comparisons and comparisons of its financial measures with other companies in Vericel’s industry. However, the non-GAAP financial measures that Vericel uses may differ from measures that other companies may use. Non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP.
Forward-Looking Statements
Vericel cautions you that all statements other than statements of historical fact included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for the forward-looking statements contained herein, they are based on current expectations about future events affecting us and are subject to risks, assumptions, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control. Our actual results may differ materially from those expressed or implied by the forward-looking statements in this press release. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “continues,” “believe,” “guidance,” “outlook,” “target,” “future,” “potential,” “goals” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “could,” “may,” or similar expressions.
Among the factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, the inherent uncertainties associated with our expectations concerning expected revenue results for the fourth quarter and full-year ended 2025, and estimates of our net income, gross margin, adjusted EBITDA margin and cash and investments as of December 31, 2025. Vericel’s revenue expectations for the fourth quarter and full-year ended 2025, as well as its estimates concerning net income, gross margin, adjusted EBITDA margin and cash and investments are preliminary, unaudited and are subject to change during ongoing internal control, review and audit procedures. Additional factors that could cause actual results to differ materially from those set forth in the forward-looking statements include, but are not limited to, uncertainties associated with our expectations regarding future revenue, growth in revenue, market penetration for MACI®, MACI Arthro®, Epicel®, and NexoBrid®, growth in profit, gross margins and operating margins, the ability to continue to scale our manufacturing operations to meet the demand for our cell therapy products, including the timely qualification of a new manufacturing facility in Burlington, Massachusetts, the ability to sustain profitability, contributions to adjusted EBITDA, the expected target surgeon audience, potential fluctuations in sales and volumes and our results of operations over the course of the year, timing and conduct of clinical trial and product development activities, timing and likelihood of the FDA’s potential approval of the use of MACI to treat cartilage defects in the ankle, the estimate of the commercial growth potential of our products and product candidates, competitive developments, changes in third-party coverage and reimbursement, including recent and future healthcare reform measures and private payor initiatives, surgeon adoption of MACI Arthro, physician and burn center adoption of NexoBrid, labor strikes, supply chain disruptions or other events or factors that might affect our ability to manufacture MACI or Epicel or affect MediWound’s ability to manufacture and supply sufficient quantities of NexoBrid to meet customer demand, including but not limited to conflicts in the Middle East region involving Israel, negative impacts on the global economy and capital markets resulting from the conflict in Ukraine and Middle East conflicts, including those associated with potential further involvement by the U.S., changes in trade policies and regulations, including the potential for increases or changes in duties, current and potentially new tariffs or quotas, lingering effects of adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, possible changes in governmental monetary and fiscal policies, including, but not limited to, Federal Reserve policies in connection with continued inflationary pressures, the impact from future regulatory, judicial and legislative changes to our industry or to the broader business landscape, including those included in the One Big Beautiful Bill Act, a shutdown of, or gridlock within the U.S. government, global geopolitical tensions and potential future impacts on our business or the economy generally stemming from a public health emergency.
These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission (SEC) on February 27, 2025, Vericel’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, filed with the SEC on November 6, 2025, and in other filings with the SEC. These forward-looking statements reflect our views as of the date hereof and Vericel does not assume and specifically disclaims any obligation to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
Investor Contact:
Eric Burns
ir@vcel.com
+1 (734) 418-4411
FAQ
What were Vericel (VCEL) preliminary total revenues for 2025?
How much of Vericel's 2025 revenue came from MACI (VCEL)?
Did Vericel (VCEL) report profitability for 2025?
What margins did Vericel (VCEL) report for 2025?
How strong was MACI performance in Q4 2025 for Vericel (VCEL)?
What is Vericel's (VCEL) cash position at year-end 2025?
When will Vericel (VCEL) begin commercial manufacturing at its new facility?
